<DOC>
	<DOC>NCT00607919</DOC>
	<brief_summary>This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)</brief_summary>
	<brief_title>Treatment of ADHD With Atomoxetine in Children &amp; Adolescents With ADHD &amp; Comorbid Dyslexia</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Dyslexia</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSMIV) criteria for AttentionDeficit/Hyperactivity Disorder (ADHD) patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient child or adolescent patients must be 10 to 16 years old must be able to communicate in English must be able to swallow capsules be reliable to keep appointments for clinic visits and all related tests patients who weigh less than 25 Kg or greater than 70 Kg patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder females who are pregnant or breastfeeding patients with a history of severe allergy to more than one class of medications patients with documented history of bipolar I or bipolar II disorder, or psychosis</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>